scholarly journals The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study

2017 ◽  
Vol 176 (5) ◽  
pp. 1366-1369 ◽  
Author(s):  
S.K. Grewal ◽  
J. Wan ◽  
M.R. Denburg ◽  
D.B. Shin ◽  
J. Takeshita ◽  
...  
Keyword(s):  
Cohort Study ◽  
Iga Nephropathy ◽  
Population Based ◽  
Glomerular Disease

scholarly journals Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study

2019 ◽  
Vol 30 (5) ◽  
pp. 866-876 ◽  
Author(s):  
Simon Jarrick ◽  
Sigrid Lundberg ◽  
Adina Welander ◽  
Juan-Jesus Carrero ◽  
Jonas Höijer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Life Expectancy ◽  
Iga Nephropathy ◽  
Absolute Risk ◽  
Reference Population ◽  
Population Based ◽  
Increased Risk ◽  
Using Data ◽  
Increases In Risk

BackgroundThe clinical course of IgA nephropathy (IgAN) varies from asymptomatic nonprogressive to aggressive disease, with up to one in four patients manifesting ESRD within 20 years of diagnosis. Although some studies have suggested that mortality appears to be increased in IgAN, such studies lacked matched controls and did not report absolute risk.MethodsWe conducted a population-based cohort study in Sweden, involving patients with biopsy-verified IgAN diagnosed in 1974–2011; main outcome measures were death and ESRD. Using data from three national registers, we linked 3622 patients with IgAN with 18,041 matched controls; we also conducted a sibling analysis using 2773 patients with IgAN with 6210 siblings and a spousal analysis that included 2234 pairs.ResultsDuring a median follow-up of 13.6 years, 577 (1.1%) patients with IgAN died (10.67 per 1000 person-years) compared with 2066 deaths (0.7%) in the reference population during a median follow-up of 14.1 years (7.45 per 1000 person-years). This corresponded to a 1.53-fold increased risk and an absolute excess mortality of 3.23 per 1000 person-years (equaling one extra death per 310 person-years) and a 6-year reduction in median life expectancy. Similar increases in risk were seen in comparisons with siblings and spouses. IgAN was associated with one extra case of ESRD per 54 person-years. Mortality preceding ESRD was not significantly increased compared with controls, spouses, or siblings. Overall mortality did not differ significantly between patients with IgAN-associated ESRD and patients with ESRD from other causes.ConclusionsPatients with IgAN have an increased mortality compared with matched controls, with one extra death per 310 person-years and a 6-year reduction in life expectancy.

scholarly journals Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study

2020 ◽  
pp. ASN.2020060848
Author(s):  
Johanna Rehnberg ◽  
Adina Symreng ◽  
Jonas F. Ludvigsson ◽  
Louise Emilsson
Keyword(s):  
Inflammatory Bowel Disease ◽  
Logistic Regression ◽  
Cohort Study ◽  
Iga Nephropathy ◽  
Bowel Disease ◽  
Cox Regression ◽  
Population Based ◽  
Swedish Population ◽  
Increased Risk ◽  
Inflammatory Bowel

BackgroundCase reports suggest an association between inflammatory bowel disease, a chronic autoimmune condition linked to increased circulating IgA levels, and IgA nephropathy, the most common form of primary GN and a leading cause of ESKD.MethodsIn a Swedish population-based cohort study, we compared 3963 biopsy-verified IgA nephropathy patients with 19,978 matched controls between 1974 and 2011, following up participants until 2015. Inflammatory bowel disease data and ESKD status were obtained through national medical registers. We applied Cox regression to estimate hazard ratios (HRs) for future inflammatory bowel disease in IgA nephropathy and conditional logistic regression to assess risk of earlier inflammatory bowel disease in IgA nephropathy. We also explored whether inflammatory bowel disease affects development of ESKD in IgA nephropathy.ResultsDuring a median follow-up of 12.6 years, 196 (4.95%) patients with IgA nephropathy and 330 (1.65%) matched controls developed inflammatory bowel disease (adjusted HR, 3.29; 95% confidence interval [95% CI], 2.73 to 3.96). Inflammatory bowel disease also was more common before a confirmed IgA nephropathy diagnosis. Some 103 (2.53%) IgA nephropathy patients had an earlier inflammatory bowel disease diagnosis compared with 220 (1.09%) controls (odds ratio [OR], 2.37; 95% CI, 1.87 to 3.01). Both logistic regression (OR, 2.60; 95% CI, 2.02 to 3.35) and time-varying Cox regression (HR, 1.84; 95% CI, 1.33 to 2.55) demonstrated that inflammatory bowel disease was associated with increased ESKD risk in patients with IgA nephropathy.ConclusionsPatients with IgA nephropathy have an increased risk of inflammatory bowel disease both before and after their nephropathy diagnosis. In addition, among patients with IgA nephropathy, comorbid inflammatory bowel disease elevates the risk of progression to ESKD.

Estimated GFR and Incidence of Major Surgery: A Population-Based Cohort Study

2020 ◽  
Author(s):  
Tyrone G. Harrison ◽  
Shannon M. Ruzycki ◽  
Matthew T. James ◽  
Paul E. Ronksley ◽  
Kelly B. Zarnke ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Major Surgery ◽  
Estimated Gfr

Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study

2021 ◽  
Vol 184 (1) ◽  
pp. 19-28
Author(s):  
Alexander A Leung ◽  
Janice L Pasieka ◽  
Martin D Hyrcza ◽  
Danièle Pacaud ◽  
Yuan Dong ◽  
...  
Keyword(s):  
Cohort Study ◽  
Administrative Data ◽  
Laboratory Data ◽  
Population Based ◽  
Incidence Rates ◽  
Primary Objective ◽  
Administrative Databases ◽  
Secondary Objective ◽  
True Frequency ◽  
Clinical Records

Objective Despite the significant morbidity and mortality associated with pheochromocytoma and paraganglioma, little is known about their epidemiology. The primary objective was to determine the incidence of pheochromocytoma and paraganglioma in an ethnically diverse population. A secondary objective was to develop and validate algorithms for case detection using laboratory and administrative data. Design Population-based cohort study in Alberta, Canada from 2012 to 2019. Methods Patients with pheochromocytoma or paraganglioma were identified using linked administrative databases and clinical records. Annual incidence rates per 100 000 people were calculated and stratified according to age and sex. Algorithms to identify pheochromocytoma and paraganglioma, based on laboratory and administrative data, were evaluated. Results A total of 239 patients with pheochromocytoma or paraganglioma (collectively with 251 tumors) were identified from a population of 5 196 368 people over a period of 7 years. The overall incidence of pheochromocytoma or paraganglioma was 0.66 cases per 100 000 people per year. The frequency of pheochromocytoma and paraganglioma increased with age and was highest in individuals aged 60–79 years (8.85 and 14.68 cases per 100 000 people per year for males and females, respectively). An algorithm based on laboratory data (metanephrine >two-fold or normetanephrine >three-fold higher than the upper limit of normal) closely approximated the true frequency of pheochromocytoma and paraganglioma with an estimated incidence of 0.54 cases per 100 000 people per year. Conslusion The incidence of pheochromocytoma and paraganglioma in an unselected population of western Canada was unexpectedly higher than rates reported from other areas of the world.

Thyroid function and metabolic syndrome: results from the population-based LifeLines Cohort study

2017 ◽  
Author(s):  
Bruce Wolffenbuttel ◽  
Hanneke Wouters ◽  
Sandra Slagter ◽  
Waateringe Robert van ◽  
Vliet-Ostaptchouk Jana van ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Cohort Study ◽  
Thyroid Function ◽  
Population Based
Sign in / Sign up

Export Citation Format

Share Document